Turning Point Therapeutics, Inc.

NasdaqGS:TPTX Stock Report

Market Cap: US$3.8b

Turning Point Therapeutics Valuation

Is TPTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TPTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate TPTX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TPTX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TPTX?

Key metric: As TPTX barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for TPTX. This is calculated by dividing TPTX's market cap by their current book value.
What is TPTX's PB Ratio?
PB Ratio4.8x
BookUS$793.02m
Market CapUS$3.81b

Price to Book Ratio vs Peers

How does TPTX's PB Ratio compare to its peers?

The above table shows the PB ratio for TPTX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average11.9x
KDNY Chinook Therapeutics
8.1x22.6%US$2.9b
ADMA ADMA Biologics
22.2x30.5%US$5.1b
ALPN Alpine Immune Sciences
13.4x-9.9%US$4.5b
CPRX Catalyst Pharmaceuticals
4x17.5%US$2.5b
TPTX Turning Point Therapeutics
4.8x24.7%US$3.8b

Price-To-Book vs Peers: TPTX is good value based on its Price-To-Book Ratio (4.8x) compared to the peer average (13.2x).

Price to Book Ratio vs Industry

How does TPTX's PB Ratio compare vs other companies in the US Biotechs Industry?

59 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$594.06m
AMRN Amarin
0.4x-7.7%US$217.60m
IMAB I-Mab
0.4x1.8%US$76.61m
MGX Metagenomi
0.3x-23.2%US$75.22m
TPTX 4.8xIndustry Avg. 1.9xNo. of Companies78PB01.63.24.86.48+
59 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: TPTX is expensive based on its Price-To-Book Ratio (4.8x) compared to the US Biotechs industry average (1.5x).

Price to Book Ratio vs Fair Ratio

What is TPTX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TPTX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio4.8x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate TPTX's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Collegium Pharmaceutical

US$993.0m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$31.19

7D

4.8%

1Y

22.3%

IQVIA Holdings

US$37.0b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.23

7D

5.2%

1Y

-4.6%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$57.86

7D

3.9%

1Y

15.0%